Comment Targeting interleukin 23 for Crohn's disease finding the right drug for the right patient

Brian Feagan and colleagues1 report in The Lancet the shortterm 12 weeks efficacy and safety of risankizumab a humanised monoclonal antibody targeting the p19 subunit of interleukin 23 in patients with moderatetosevere Crohn's disease Crohn's disease activ...